Calming Cytokine Storm in Pneumonia by Targeted Delivery of TPCA-1 Using Platelet-Derived Extracellular Vesicles

Ma, Qingle; Fan, Qin; Xu, Jialu; Bai, Jinyu; Han, Xiao; Dong, Ziliang; Zhou, Xiaozhong; Liu, Zhuang; Gu, Zhen; Wang, Chao

doi:10.1016/j.matt.2020.05.017

Cited by 126 publications

(125 citation statements)

References 47 publications

(51 reference statements)

Supporting

Mentioning

124

Contrasting

Order By: Relevance

“…In wound-healing models platelet-derived EVs were shown to improve cell proliferation, migration, and angiogenesis via phosphoinositide 3-kinase (PI3K)-Akt and mitogen-activated protein kinase (MAPK)-Erk signaling, and the interaction between TGF-β and yes-associated protein (YAP) [ 33 ], which could help to elucidate the mechanism by which convalescent plasma shows positive results. There is another study showing the effectiveness of engineered platelet-derived EVs loaded with TPCA-1 to treat pneumonia [ 35 ]. This treatment inhibited the inflammation and reduced the local cytokine storm in a mouse model targeting selectively inflammatory sites.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 and Extracellular Vesicles: An Intriguing Interplay

Pócsfalvi

Mammadova

Juarez

et al. 2020

Kidney Blood Press Res

View full text Add to dashboard Cite

Background: The outbreak of severe acute respiratory syndrome β-coronavirus 2 (SARS-CoV-2) has the potential to become a long-lasting global health crisis. The number of people infected with the novel coronavirus has surpassed 22 million globally, resulting in over 700,000 deaths with more than 15 million people having recovered (https://covid19.who.int). Enormous efforts are underway for rapid vaccine and treatment developments. Amongst the many ways of tackling the novel coronavirus disease 2019 (COVID-19) pandemic, extracellular vesicles (EVs) are emerging. Summary: EVs are lipid bilayer-enclosed structures secreted from all types of cells, including those lining the respiratory tract. They have established roles in lung immunity and are involved in the pathogenesis of various lung diseases, including viral infection. In this review, we point out the roles and possible contribution of EVs in viral infections, as well as ongoing EV-based approaches for the treatment of COVID-19, including clinical trials. Key Messages: EVs share structural similarities to viruses and recent findings demonstrate that viruses exploit EVs for cellular exit and EVs exploit viral entry mechanisms for cargo delivery. Moreover, EV-virus interplay could be exploited for future antiviral drug and vaccine development. EV-based therapies, especially the mesenchymal stem cell-derived EVs, are being intensively studied for the treatment of COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 and Extracellular Vesicles: An Intriguing Interplay

Pócsfalvi

Mammadova

Juarez

et al. 2020

Kidney Blood Press Res

View full text Add to dashboard Cite

show abstract

“…Lessons from nanotechnology-based cancer immunotherapy can inform treatment designs to modulate the cytokine storm by delivering anti-inflammatory drugs or inhibitors to inflammation sites. In particular, bioresponsive nanomaterials 186 – 188 that target inflammation sites can deliver anti-inflammatory drugs and inhibitors. However, the targeting efficacy and payload leakage still need to be optimized to decrease side effects.…”

Section: Possibilities For Materials Sciencementioning

confidence: 99%

A materials-science perspective on tackling COVID-19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…For example, platelet-derived nanomaterials can be introduced to encapsulate [5-(p-fluorophenyl)-2-ureido]thiophene-3-carboxamide (TPCA-1) to target the pneumonia site and calm cytokine storm. [ 81 ] Moreover, antioxidant nanomaterials such as cerium dioxide nanoparticles can also be utilized to eliminate reactive oxygen species (ROS) in the inflammatory site. [ 82 ]…”

Section: Outlooksmentioning

confidence: 99%